Register for one of these upcoming trainings!
Virtual meeting
Via Zoom
Description
This is a one-hour training that prepares nurses offering medication for opioid-use disorder to manage addiction treatment with long-acting injectable buprenorphine. Topics covered will include the pharmacology of long-acting injectable buprenorphine; patient selection; medication storage and administration; clinical logistics; side effects; supplemental dosing; lessons learned from the field; and billing and specialty pharmacies. We will also have an open discussion to learn from each other’s experiences with using this treatment.
Objectives
By the end of the training, participants will have the knowledge necessary to:
- Explain the pharmacology and side effects of monthly injectable buprenorphine.
- Recall processes of patient selection, storage, and administration of injectable buprenorphine.
- Identify patients who may need supplemental dosing during treatment with injectable buprenorphine.
- Describe related specialty pharmacy protocols.
Intended audience
Nurses, medical assistants, and all others working with patients on injectable buprenorphine are welcome and encouraged to attend.
Speakers
Jessica Kemp, RN, CARN
Annie Potter, MSN, MPH, NP, CARN-AP
Nancy Regan, MSN, NP, CNM
Credits
- Nursing (1.00) ; Pharmacology (1.00)
- Social work (1.00)
- LADC (1.00)
- CADC (1.00)
- LMHC (1.00)
Please visit the event page on the Grayken TTA website for accreditation information.
Sponsored by
Boston Medical Center Grayken Center for Addiction TTA, Massachusetts Department of Public Health, Bureau of Substance Addiction Services (DPH/BSAS)
Funding for out of state attendees is provided by the Opioid Response Network (ORN).
Funding for this initiative was made possible (in part) by grant no. 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
